๐ฐ Greg Korbutt News
Greg Korbutt News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Greg Korbutt. Real-time updates on events, politics, business and more.
September 8, 2023
Gillian Rutherford โข Promising results in innovative diabetes treatment method that enhances the safety of insulin cell transplants
March 9, 2021
Date Time Made-in-Alberta COVID-19 vaccine candidate goes to clinical trials A made-in-Alberta COVID-19 vaccine is taking a major step forward on the path to Health Canada approval with the start of a Phase 1 clinical trial. Entos Pharmaceuticals, an Edmonton company led by CEO and University of Alberta researcher John Lewis, has shipped a vaccine for testing to the Canadian Centre for Vaccinology in Halifax. The clinical trial will test the safety of the DNA-based vaccine in 72 participants, s...
March 9, 2021
ย EDMONTON -- An Alberta-developed COVID-19 vaccine using new technology is one step closer to starting clinical trials. John Lewis, University of Alberta professor and CEO of Entos Pharmaceuticals, has shipped a vaccine for further testing to the Canadian Centre for Vaccinology in Halifax โ a step forward toward its Health Canada approval. The made-in-Alberta COVID-19 vaccine will commence its Health Canada Phase 1 human clinical trial with the aim of moving it to a larger Phase 2 trial ...
February 25, 2021
in the . Entos announces partnership with The Ottawa Hospitals Biotherapeutics Manufacturing Centre (BMC) to fill Covigenix VAX-001 in vials. BMC and ACTM will collaborate to boost Canadas biotherapeutics manufacturing capacity. EDMONTON, AB, Feb. 25, 2021 /CNW/ -ย Entos Pharmaceuticals (Entos), a biotechnology company developing genetic medicines with its Fusogenix nucleic acid delivery platform, is excited to work with Alberta Cell Therapy Manufacturing and The Ottawa Hospitals Biotherapeu...
December 18, 2020
Date Time Share CIHR and JDRF funding drives efforts to find new stem cell-based therapies for Type 1 diabetes University of Alberta researchers are among two Canadian research teams chosen for significant new funding from the Government of Canada and JDRF Canada to develop new stem cell-based therapies for treating Type 1 diabetes. The projects will each receive $1.5 million from the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD) along with ...